– Study demonstrates proximal hypoglossal nerve stimulation (pHGNS) yielded clinically significant responses and sustained improvements over time – First rigorous RCT study design in HGNS space supports pHGNS becoming a competitive option in the treatment landscape LONDON --(BUSINESS WIRE)--Apr.
LONDON --(BUSINESS WIRE)--Mar. 25, 2026-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time ( 8 a.m. Eastern Daylight Time).
– First and only hypoglossal nerve stimulation therapy approved in the U.S. without complete concentric collapse contraindication or warning language – Next-generation, MRI-compatible device expected to launch in the first half of 2027, pending FDA supplement review LONDON --(BUSINESS WIRE)--Mar.
– Delivered double-digit reported and organic revenue growth and continued operating margin expansion for full-year 2025 – Issued full-year 2026 guidance, including constant-currency revenue growth between 6.0% and 7.0% and adjusted diluted earnings per share in the range of $4.15 to $4.25 –
LONDON --(BUSINESS WIRE)--Jan. 20, 2026-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2025 results on Wed., Feb. 25, 2026 , at 1 p.m. London time ( 8 a.m. Eastern Standard Time ).